{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:48:42Z","timestamp":1792792122966,"version":"4.5.0"},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:sec id=\"ab-ebr240012-4\"><jats:title>Importance<\/jats:title><jats:p>Randomized clinical trials have shown the safety and efficacy of faricimab as a novel vascular endothelial growth factor and angiopoietin-2 inhibitor in the treatment of neovascular age-related macular degeneration (nAMD) and macular edema of various etiologies. However, more rare adverse events may not be considered in clinical trials.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ebr240012-5\"><jats:title>Objective<\/jats:title><jats:p>To describe 3 eyes that developed irreversible vision loss following initial mild intraocular inflammation (IOI) to faricimab.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ebr240012-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This retrospective case series from a single academic tertiary referral center (University of Nebraska Medical Center) from October 2023 to August 2024 included 3 patients who developed occlusive retinal vasculitis (ORV) following an initial sensitization with intravitreal faricimab. Two eyes were being treated with faricimab for nAMD, and the other 2 eyes were treated for diabetic macular edema.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ebr240012-7\"><jats:title>Intervention<\/jats:title><jats:p>Patients exposed to faricimab after the prior development of mild IOI.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ebr240012-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Clinical symptoms, signs, and clinical course of patients who were diagnosed with ORV following rechallenge with faricimab.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ebr240012-9\"><jats:title>Results<\/jats:title><jats:p>Mild IOI developed in 4 eyes following faricimab, and ORV developed in 3 eyes with repeated challenge. This resulted in profound, irreversible vision loss, despite treatment with topical and systemic steroids. In the eye that did not develop ORV following rechallenge, there have been no repeated adverse events despite restarting intravitreal faricimab injections.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ebr240012-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Given these observations with repeated challenge, caution is advisable when using the same biologic after the development of even mild IOI with prior injection. It appears an immunological memory response is elicited with these repeated exposures, resulting in the development of ORV.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2024.5889","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T16:32:24Z","timestamp":1737649944000},"page":"232","source":"Crossref","is-referenced-by-count":20,"title":["Inflammation and Occlusive Retinal Vasculitis Post Faricimab"],"prefix":"10.1001","volume":"143","author":[{"given":"Will","family":"Bruening","sequence":"first","affiliation":[{"name":"Truhlsen Eye Center, Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Kim","sequence":"additional","affiliation":[{"name":"Truhlsen Eye Center, Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Yeh","sequence":"additional","affiliation":[{"name":"Truhlsen Eye Center, Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pukhraj","family":"Rishi","sequence":"additional","affiliation":[{"name":"Truhlsen Eye Center, Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Conrady","sequence":"additional","affiliation":[{"name":"Truhlsen Eye Center, Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha"},{"name":"Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"ebr240012r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.07.020","article-title":"Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab.","author":"Sim","journal-title":"Ophthalmol Retina"},{"issue":"10326","key":"ebr240012r2","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"ebr240012r3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ajo.2024.08.008","article-title":"Severe intraocular inflammation after intravitreal injection of faricimab: a single-site case series of six patients.","volume":"269","author":"Ben Ghezala","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"ebr240012r4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review.","volume":"7","author":"Anderson","year":"2021","journal-title":"Int J Retina Vitreous"},{"issue":"11","key":"ebr240012r5","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.ophtha.2008.05.007","article-title":"Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration.","volume":"115","author":"Wickremasinghe","year":"2008","journal-title":"Ophthalmology"},{"issue":"20","key":"ebr240012r6","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration.","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"ebr240012r7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamaophthalmol.2024.0530","article-title":"Severe intraocular inflammation following intravitreal faricimab.","volume":"142","author":"Thangamathesvaran","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"ebr240012r8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ajo.2010.08.047","article-title":"Appropriate use and reporting of uncontrolled case series in the medical literature.","volume":"151","author":"Kempen","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"ebr240012r9","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1080\/09273948.2024.2361834","article-title":"Intra-ocular inflammation and occlusive retinal vasculitis following intravitreal injections of faricimab: a case report.","volume":"32","author":"Chen","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"ebr240012r10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/24741264241253899","article-title":"Faricimab-associated retinal vasculitis.","volume":"8","author":"Siddiqui","year":"2024","journal-title":"J Vitreoretin Dis"},{"issue":"5","key":"ebr240012r11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1001\/jamaophthalmol.2024.0928","article-title":"Association of occlusive retinal vasculitis with intravitreal faricimab.","volume":"142","author":"Li","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"ebr240012r12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12348-024-00429-7","article-title":"Occlusive retinal vasculitis associated with intravitreal faricimab injections.","volume":"14","author":"Reichel","year":"2024","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"1","key":"ebr240012r13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/24741264231220224","article-title":"Retinal vasculitis after intravitreal pegcetacoplan: report from the ASRS Research and Safety in Therapeutics (ReST) Committee.","volume":"8","author":"Witkin","year":"2023","journal-title":"J Vitreoretin Dis"},{"key":"ebr240012r14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ajo.2018.01.030","article-title":"Vancomycin-associated hemorrhagic occlusive retinal vasculitis: a clinical-pathophysiological analysis.","volume":"188","author":"Todorich","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"27","key":"ebr240012r15","doi-asserted-by":"publisher","first-page":"11187","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies.","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"ebr240012r16","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1080\/09273948.2019.1611874","article-title":"Rituximab-associated retinal occlusive vasculopathy: a case report and literature review.","volume":"28","author":"Conrady","year":"2020","journal-title":"Ocul Immunol Inflamm"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2829210\/jamaophthalmology_bruening_2025_br_240012_1741981301.4623.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T21:42:35Z","timestamp":1742506955000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2829210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.5889","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}